Mangiferin induces cell death against rhabdomyosarcoma through sustained oxidative stress. 2015

Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu, India.

BACKGROUND Embryonic rhabdomyosarcoma (RD) is the most prevalent type of cancer among children. The present study aimed to investigate cell death induced by mangiferin in RD cells. METHODS The Inhibitory concentration (IC50) value of mangiferin was determined by an MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay. Cell death induced by mangiferin against RD cells was determined through lactate dehydrogenase and nitric oxide release, intracellular calcium levels, reactive oxygen species generation, antioxidant status, mitochondrial calcium level, and mitochondrial membrane potential. Furthermore, acridine orange/ethidium bromide staining was performed to determine early/late apoptotic event. RESULTS Mangiferin induced cell death in RD cells with an IC50 value of 70 μM. The cytotoxic effect was reflected in a dose-dependent increase in lactate dehydrogenase leakage and nitric oxide release during mangiferin treatment. Mangiferin caused dose dependent increase in reactive oxygen species generation, intracellular calcium levels with subsequent decrease in antioxidant status (catalase, superoxide dismutase, glutathione-S-transferase, and glutathione) and loss of mitochondrial membrane potential in RD cells. Further data from fluorescence microscopy suggest that mangiferin caused cell shrinkage and nuclear condensation along with the occurrence of a late event of apoptosis. CONCLUSIONS Results of the present study shows that mangiferin can act as a promising chemopreventive agent against RD by inducing sustained oxidative stress.

UI MeSH Term Description Entries

Related Publications

Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
January 2016, Oncology reports,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
August 1999, Cancer research,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
November 2001, American journal of physiology. Cell physiology,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
August 2022, Zhongguo shi yan xue ye xue za zhi,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
January 2018, Sub-cellular biochemistry,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
March 2021, Clinical and experimental pharmacology & physiology,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
May 2019, Aging,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
August 2008, Molecular cancer therapeutics,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
November 2019, Journal of cellular physiology,
Vishwanadha Vijaya Padma, and Palanisamy Kalaiselvi, and Rangasamy Yuvaraj, and M Rabeeth
September 2017, Journal of photochemistry and photobiology. B, Biology,
Copied contents to your clipboard!